Akebia Therapeutics (NASDAQ:AKBA) CFO Erik Ostrowski Sells 56,019 Shares of Stock

Posted by George Bondi on Jul 2nd, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) CFO Erik Ostrowski sold 56,019 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $1.11, for a total transaction of $62,181.09. Following the completion of the sale, the chief financial officer owned 616,616 shares in the company, valued at $684,443.76. This represents a 8.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Akebia Therapeutics Stock Up 6.1%

Shares of NASDAQ:AKBA opened at $1.21 on Thursday. The company has a market cap of $324.59 million, a price-to-earnings ratio of -15.12 and a beta of 0.23. Akebia Therapeutics, Inc. has a 12 month low of $0.82 and a 12 month high of $4.08. The company has a 50-day moving average price of $1.11 and a 200 day moving average price of $1.31. The company has a current ratio of 1.40, a quick ratio of 1.33 and a debt-to-equity ratio of 1.33.

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). The company had revenue of $53.54 million during the quarter, compared to analysts’ expectations of $51.67 million. Akebia Therapeutics had a negative return on equity of 62.72% and a negative net margin of 8.83%. As a group, equities research analysts predict that Akebia Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on AKBA shares. Wall Street Zen cut shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Akebia Therapeutics in a report on Wednesday, May 6th. BTIG Research reissued a “buy” rating and issued a $4.00 price objective on shares of Akebia Therapeutics in a research note on Tuesday, April 7th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Akebia Therapeutics in a report on Wednesday. Finally, Zacks Research lowered Akebia Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $4.67.

Get Our Latest Report on Akebia Therapeutics

Hedge Funds Weigh In On Akebia Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AKBA. Cibc World Markets Corp purchased a new stake in Akebia Therapeutics during the fourth quarter worth $27,000. Brevan Howard Capital Management LP acquired a new stake in Akebia Therapeutics in the 2nd quarter worth about $62,000. Polymer Capital Management US LLC increased its position in shares of Akebia Therapeutics by 49.5% during the third quarter. Polymer Capital Management US LLC now owns 18,232 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 6,034 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Akebia Therapeutics by 697.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,622 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 18,037 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its position in Akebia Therapeutics by 23.0% during the first quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 4,000 shares during the last quarter. Institutional investors and hedge funds own 33.92% of the company’s stock.

About Akebia Therapeutics

(Get Free Report)

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.